4 months ago
FDA Approves Durvalumab for Advanced Endometrial Cancer Treatment
On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved AstraZeneca’s drug Durvalumab (IMFINZI®) for the treatment of primary advanced or recurrent endometrial cancer in patients with mismatch repair deficiency.
Endometrial cancer is recognized as the most common gynecologic cancer in the United States, with an estimated 66,200 new cases in 2023 alone.
Know More: https://thelifesciencesmag...
#FDAApproval #Durvalumab #EndometrialCancer #CancerTreatment #DrugApproval #MedicalBreakthrough #oncology
On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved AstraZeneca’s drug Durvalumab (IMFINZI®) for the treatment of primary advanced or recurrent endometrial cancer in patients with mismatch repair deficiency.
Endometrial cancer is recognized as the most common gynecologic cancer in the United States, with an estimated 66,200 new cases in 2023 alone.
Know More: https://thelifesciencesmag...
#FDAApproval #Durvalumab #EndometrialCancer #CancerTreatment #DrugApproval #MedicalBreakthrough #oncology
Durvalumab Gains FDA Approval For Endometrial Cancer Treatment | The Lifesciences Magazine
Durvalumab (IMFINZI®) approved by FDA for advanced endometrial cancer. Discover its PD-L1 targeting mechanism and its impact on cancer immunotherapy.
https://thelifesciencesmagazine.com/durvalumab-gains-fda-approval/
